1. Home
  2. TNXP vs NREF Comparison

TNXP vs NREF Comparison

Compare TNXP & NREF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNXP
  • NREF
  • Stock Information
  • Founded
  • TNXP 2007
  • NREF 2019
  • Country
  • TNXP United States
  • NREF United States
  • Employees
  • TNXP N/A
  • NREF N/A
  • Industry
  • TNXP Biotechnology: Pharmaceutical Preparations
  • NREF Real Estate Investment Trusts
  • Sector
  • TNXP Health Care
  • NREF Real Estate
  • Exchange
  • TNXP Nasdaq
  • NREF Nasdaq
  • Market Cap
  • TNXP 197.9M
  • NREF 233.4M
  • IPO Year
  • TNXP N/A
  • NREF 2020
  • Fundamental
  • Price
  • TNXP $15.12
  • NREF $14.49
  • Analyst Decision
  • TNXP Buy
  • NREF Hold
  • Analyst Count
  • TNXP 1
  • NREF 3
  • Target Price
  • TNXP $70.00
  • NREF $14.75
  • AVG Volume (30 Days)
  • TNXP 778.7K
  • NREF 64.4K
  • Earning Date
  • TNXP 11-10-2025
  • NREF 10-30-2025
  • Dividend Yield
  • TNXP N/A
  • NREF 13.76%
  • EPS Growth
  • TNXP N/A
  • NREF 132.43
  • EPS
  • TNXP N/A
  • NREF 3.08
  • Revenue
  • TNXP $10,299,000.00
  • NREF $151,560,000.00
  • Revenue This Year
  • TNXP $14.79
  • NREF $27.88
  • Revenue Next Year
  • TNXP $933.49
  • NREF $5.41
  • P/E Ratio
  • TNXP N/A
  • NREF $4.73
  • Revenue Growth
  • TNXP N/A
  • NREF 107.15
  • 52 Week Low
  • TNXP $6.76
  • NREF $12.14
  • 52 Week High
  • TNXP $130.00
  • NREF $18.09
  • Technical
  • Relative Strength Index (RSI)
  • TNXP 35.51
  • NREF 63.79
  • Support Level
  • TNXP $13.70
  • NREF $13.52
  • Resistance Level
  • TNXP $18.25
  • NREF $14.27
  • Average True Range (ATR)
  • TNXP 1.28
  • NREF 0.32
  • MACD
  • TNXP 0.07
  • NREF 0.11
  • Stochastic Oscillator
  • TNXP 26.08
  • NREF 93.97

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

About NREF NexPoint Real Estate Finance Inc.

NexPoint Real Estate Finance Inc is a real estate investment trust. The company provides structured financing solutions by investing in mid-sized multifamily, storage and select-service, and extended-stay hospitality properties. Its investment objective is to generate attractive, risk-adjusted returns for stockholders over the long term. The Company is focused on originating, structuring and investing in first-lien mortgage loans, mezzanine loans, preferred equity, convertible notes, multifamily properties, and common equity investments, as well as multi-family and single-family rental ("SFR") commercial mortgage-backed securities securitizations ("CMBS securitizations"), multifamily structured credit risk notes ("MSCR Notes") and mortgage-backed securities.

Share on Social Networks: